ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0486

Differences in Low-density Lipoprotein (LDL) Particle Composition and Oxidation May Underlie the Paradoxical Association of Low LDL with Higher Coronary Atherosclerosis Burden in Rheumatoid Arthritis

George Karpouzas1, Sarah Ormseth1, Elizabeth Hernandez1 and Matthew Budoff1, 1Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, CA

Meeting: ACR Convergence 2020

Keywords: Atherosclerosis, Cardiovascular, Computed tomography (CT), rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: RA – Diagnosis, Manifestations, & Outcomes II: The Heart of the Matter (0484–0488)

Session Type: Abstract Session

Session Time: 4:00PM-4:50PM

Background/Purpose: Rheumatoid arthritis (RA) patients in the lowest LDL group (< 70mg/dl) experience unexpectedly high cardiovascular risk. We first explored whether this group (Group 1) had higher coronary atherosclerosis burden compared to other LDL groups (Group 2: 70≤ LDL ≤130 and Group 3: LDL >130). We then evaluated whether differences in LDL particle composition, oxidation, or inflammation associated with low LDL in Group 1.

Methods: One hundred fifty RA patients without cardiovascular disease underwent coronary atherosclerosis evaluation with computed tomography angiography. Coronary artery calcium, number of segments with plaque (segment involvement score), stenotic severity (segment stenosis score), and extensive ( >4 segments with plaque) or obstructive disease ( >50% stenosis) were assessed. Lipoprotein classes and subclasses were directly measured. Oxidized LDL (oxLDL) was measured with monoclonal antibody E06. Chemiluminescence Elisa quantified IgG and IgM antibodies to oxLDL (anti-oxLDL) and apoB100 immune complexes. Proinflammatory cytokines were measured with Erenna Immunoassay. Robust linear and logistic regression models- adjusted for Framingham D’Agostino score and statin treatment- evaluated associations between LDL groups and plaque outcomes. Similar models evaluated adjusted differences in LDL subclasses, oxLDL, anti-oxLDL, ApoB100 immune complexes, and cytokines across LDL groups.

Results: Patients in Group 1 had higher coronary plaque burden (Figure 1A) and 2.8 times greater likelihood of extensive or obstructive disease (adjusted OR 2.82 [95% CI 1.12-7.17], P = 0.031) compared to LDL >70 groups. Group 1 had higher anti-oxLDL IgG and ApoB100 IgG immune complexes compared to other groups (Figure 2A). Among statin naïve patients, those with LDL< 70 also had higher oxLDL (Log transformed EMM 2.55 [95%CI 2.34-2.77] vs. 2.27 [95%CI 2.19-2.36], P = 0.018 for LDL >70). LDL subclass relative content in the LDL particle differed across groups. Lp(a) was higher in LDL particles in Group 1 (EMM 16.04% [95% CI 11.75-20.33], vs. 10.48% [95% CI 8.20-12.75] in Group 2, p = 0.026 and 7.41% [95% CI 0.77-14.04] in Group 3, p = 0.033). Notably, Lp(a) content strongly associated with oxLDL overall (r = 0.83, p< 0.0001). This association was stronger for Group 1 compared to others (p< 0.005, Figure 2B). No differences in RA activity, CRP, TNF-α, IL-17A, or IL-17F were seen across groups. However, Group 1 had higher IL-6 (log-transformed EMM= 1.98 [95% CI 1.64- 2.32] vs. 1.57 [1.45-1.70],P = 0.028 in Group 2 and 1.32 [95% CI 0.84-1.80],
P = 0.031 in Group 3). IL-6 associated with both IgG anti-oxLDL (p=0.015) and apoB100 immune complexes (p=0.016). IL-6 further associated with higher CAC (adjusted B 0.41 [95% CI 0.01-0.81], P= 0.049).

Conclusion: RA patients with LDL< 70 had higher coronary atherosclerosis burden. Low circulating LDL in that group may reflect higher oxidation; this was mostly linked to the larger Lp(a) relative content of LDL and its significantly higher oxidation potential in that group. Greater oxLDL further associated with higher IL-6 elaboration which may in turn augment atherosclerosis burden in Group1.

Figure 1. Coronary attherosclerosis burden across different LDLgroups. SIS=segment involvement score, SSS= segment stenosis score, CAC-ln=log-transformed coronary artery calcium score.

Figure 2. A. Patients with LDL < 70mg/dl (Group 1) have higher levels of IgG antibodies against oxidized LDL and IgG immune complexes of apoB100. B. Lp(a) relative content in the LDL particle strongly associates with oxidation. This association is parti- cularly strong for Group 1.


Disclosure: G. Karpouzas, None; S. Ormseth, None; E. Hernandez, None; M. Budoff, None.

To cite this abstract in AMA style:

Karpouzas G, Ormseth S, Hernandez E, Budoff M. Differences in Low-density Lipoprotein (LDL) Particle Composition and Oxidation May Underlie the Paradoxical Association of Low LDL with Higher Coronary Atherosclerosis Burden in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/differences-in-low-density-lipoprotein-ldl-particle-composition-and-oxidation-may-underlie-the-paradoxical-association-of-low-ldl-with-higher-coronary-atherosclerosis-burden-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differences-in-low-density-lipoprotein-ldl-particle-composition-and-oxidation-may-underlie-the-paradoxical-association-of-low-ldl-with-higher-coronary-atherosclerosis-burden-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology